S3 Ep28: The European Energy Crisis w/ Alexander Stahel

00:00 - Introduction
03:50 - Career History
12:32 - Building teams, Building Companies
17:02 - Mining is a long term investment
21:54 - The Mining Cycles
25:22 - Responsible Mining
28:41 - Ewoyaa Lithium Project
33:40 - A Commodiy demand never before seen in a lifetime
39:33 - Atlantic Lithium Roadmap
43:28 - Time at Premier African Minerals
46:27 - Final Thoughts & Goals for 2023

In this podcast Mark Fairbairn & Kenny Russell talk to Allan Syms the Exceutive Chairman of Cizzle Biotech. The compnay are working on developing a blood test to detect early stage lung cancer. With 13 years of research already behind them, their IPO June 2021 opened the way to develop the science into a marketable product. 

00:00 - Introduction to Allan
09:40 - Allan's Interest in Science 
5:14 - The Jump into Industry
22:56 - Working for Big Pharma
25:35 - Scientist or Business Man?
29:16 - Failures Along the Way
32:07 - Allan's Joins Cizzle 
35:58 - The Cizzle Investment Case

Mark Fairbairn & Alexander Stahel sit down to discuss the EU energy crisis. What has caused it? How bad could it get? And how can people prepare? 

00:00 - Introduction & Data Points 
03:18 - Electricity More Important than Gas
08:15 - Rising Costs & Blackouts
11:15 - Why are we in this situation?
19:14 - Pricing/Availability & The Netherlands
24:50 - Lehman Brothers Moment for Energy
34:11 - Scandinavian Situation
38:57 - UK Situation
45:50 - Replacing LNG Shortfall (Nord Stream)
53:18 - Gas/Elec Crisis is here to stay
58:40 - How Can People Prepare?

Doc Holiday joins us again as we discuss the markets in general, IPO's and a few stocks: #CGO, #OCTP, #POLB, #ORPH, #FCM

00:00 - Introduction
02:51 - Energy & This Winter
12:47 - IPO's & Cash Shells
19:15 - First Class Metals
24:32 - Open Orphan
27:25 - Poolbeg Pharma
32:50 - Oxford Cannabinoid Technologies
37:50 - Bottom of Market, Picking Stocks & Mindset
58:05 - Contango Holdings

In this eppisode we talk to the Chief Scientific Officer at Oxford Cannabinoid and get an insight into his extensive science background, the science of cannabis medicine, the treatments the company are developing & the development process.

Although Valentino is a scientist at heart he is not oblivious to the interests and concerns of investors and he wants the scientific success to deliver returns for shareholders.

00:00 - Introduction & Background
22:06 - Cannabis/Cannabinoid Science
27:57 - The Programmes
33:46 - Development Process, Clinical Trials 
39:26 - Aligning with Investors